Adi Raviv - 01 Jan 2023 Form 3 Insider Report for BiondVax Pharmaceuticals Ltd. (BVXV)

Role
Director
Signature
/s/ Adi Raviv
Issuer symbol
BVXV
Transactions as of
01 Jan 2023
Transactions value $
$0
Form type
3
Filing time
03 Jan 2023, 14:04:16 UTC
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BVXV Ordinary Shares 66,800 01 Jan 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BVXV Stock Options (right to buy) 01 Jan 2023 Ordinary Shares 720,000 $0.202 Direct F1, F2
holding BVXV Stock Options (right to buy) 01 Jan 2023 Ordinary Shares 1,000,000 $0.174 Direct F1, F3
holding BVXV Restricted Share Units 01 Jan 2023 Ordinary Shares 133,200 Direct F1, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents four hundred Ordinary Shares.
F2 Stock options were granted on March 24, 2020 and are fully vested.
F3 Stock options were granted on April 6, 2021, and vest on a monthly basis during a period of three years.
F4 Restricted share units were granted on April 6, 2021 and vest on a monthly basis during a period of three years.
F5 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share.